Cargando…
Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
BACKGROUND: In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has show...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142681/ https://www.ncbi.nlm.nih.gov/pubmed/30223869 http://dx.doi.org/10.1186/s13063-018-2858-2 |